Dyne Therapeutics, Inc. (DYN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 28.75 |
| Open | 28.30 |
| Bid | 27.63 x 400 |
| Ask | 27.72 x 200 |
| Day's Range | 27.04 - 28.37 |
| 52 Week Range | 6.40 - 30.27 |
| Volume | |
| Avg. Volume | 1,237,787 |
| Market Cap | 2.419B |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.98 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.22 |
Simply Wall St.We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- GuruFocus.com
Dyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst Projections
Overview of Financial Performance and Future Prospects
GlobeNewswireDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights. “I am excited about
© 2024 Yahoo. All rights reserved.